Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Cash & Equivalents (2017 - 2024)

Solid Biosciences' Cash & Equivalents history spans 8 years, with the latest figure at $64.4 million for Q3 2024.

  • For Q3 2024, Cash & Equivalents rose 31.32% year-over-year to $64.4 million; the TTM value through Sep 2024 reached $64.4 million, up 31.32%, while the annual FY2022 figure was $155.4 million, 30.43% up from the prior year.
  • Cash & Equivalents for Q3 2024 was $64.4 million at Solid Biosciences, down from $95.9 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $268.5 million in Q1 2021 and bottomed at $24.8 million in Q3 2020.
  • The 5-year median for Cash & Equivalents is $113.6 million (2021), against an average of $115.5 million.
  • The largest annual shift saw Cash & Equivalents skyrocketed 342.3% in 2021 before it crashed 72.93% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $154.7 million in 2020, then decreased by 23.01% to $119.1 million in 2021, then soared by 30.43% to $155.4 million in 2022, then tumbled by 68.44% to $49.0 million in 2023, then surged by 31.32% to $64.4 million in 2024.
  • Per Business Quant, the three most recent readings for SLDB's Cash & Equivalents are $64.4 million (Q3 2024), $95.9 million (Q2 2024), and $117.6 million (Q1 2024).